What We're Reading: Page 315
Industry reads hand-picked by our editors
Apr 12, 2017
-
TheStreet
For these small-cap biotech CEOs, stock promotion, not drug development, was priority No. 1
-
Forbes
Democrats propose a $2 billion prize fund for new antibiotics
-
MIT Technology Review
Can “digital therapeutics” be as good as drugs?
-
HR Dive
Employers 'relieved' over AHCA's demise, but still seeking specialty pharma assistance
Apr 11, 2017
-
Reuters
SEC targets fake stock news on financial websites
-
Axios
Merck's CEO doubles his pay
-
The Wall Street Journal
China emerges as powerhouse for biotech drugs
-
Kaiser Health News
Drugmakers help turn patients with rare diseases into D.C. lobbyists
Apr 10, 2017
Apr 07, 2017
-
Harvard Business Review
How pharma companies game the system to keep drugs expensive
-
Bloomberg
Ailing Novo seeks cure with diabetes drug targeting fat too
-
Reuters
Experts want special clinics to prescribe ketamine as antidepressant
-
Business Insider
University of California researchers are trialling a vaccine that could be a game-changer for anyone with acne
Apr 06, 2017
-
Boston Business Journal
Former Ariad CEO joins a familiar face on board of The Medicines Co., hinting at a sale
-
NPR
How flawed science is undermining good medicine
-
CNBC
Google's parent company is vacuuming up top talent in health care and biotech
-
Nature
CRISPR studies muddy results of older gene research
-
Phys.org
How computers are searching for drugs of the future
Apr 05, 2017
Apr 04, 2017
-
Financial Times
Teva investor warns of rebellion as pressure mounts
-
ProPublica
Tom Price’s $150,000-plus stock windfall
-
MIT Technology Review
U.S. government moves forward with tests of novel Zika vaccine
Previous
